US › Healthcare

Pasithea Therapeutics Corp (KTTA)

US · Healthcare · Biotechnology

$0.42+2.44%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.3M

EPS

$-0.16

EPS estimate

$-0.16

EPS came in at -0.16 against a street estimate of -0.16 — a beat of 0.0%.

Key statistics

Market cap

$15.6M

Forward P/E

0.0

P/B

0.34

Book value

$1.49

EPS (TTM)

$-1.59

52-week high

$2.06

52-week low

$0.28

50-day MA

$0.51

200-day MA

$0.68

Beta

0.34

Analyst view

Analysts rate Pasithea Therapeutics Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders

1.11%

Institutions

63.23%

Largest institutional holders

Fund	Stake
Cable Car Capital LLC	8.98%
Stonepine Capital Management Llc	6.59%
HHG PLC	6.28%
Jupiter Topco LLC	6.28%
Adage Capital Partners Gp LLC	6.28%
Opaleye Management Inc	6.14%
Ameriprise Financial Inc	5.58%
Squadron Capital Management LLC	2.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pasithea Therapeutics Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.